Genetic engineering and de-extinction technologies
Strategic Profile
The company develops genetic engineering and reproductive technology for conservation biology. The company has made breakthroughs such as generating the first de novo assembled mammoth genome and engineering elephant stem cells—advances that are already aiding endangered species like elephants. Its work on the woolly mammoth involves genetic adaptations that could rewild the tundra, slowing permafrost thaw and mitigating climate change.
Cyborg Score Rationale
Colossal demonstrates exceptional scientific credentials, substantial capital ($435M raised as of January 2025), rapid technical breakthroughs (dire wolf pups in April 2025, artificial egg system in June 2026), and elite investor backing. However, scientific controversy regarding de-extinction feasibility and regulatory uncertainty around species reintroduction temper the outlook.
Top Insights
In 2025, the company achieved $10 billion valuation, becoming the first Texas-based startup to reach decacorn status.
In April 2025, three genetically modified dire wolf pups were born using DNA extracted from fossils—a 13,000-year-old tooth and a 72,000-year-old ear bone—and gray wolf cells.
Colossal successfully hatched 26 chicks using an artificial egg system that can incubate bird embryos without a natural shell, advancing de-extinction of avian species.
The Colossal Foundation, established in October 2024, currently supports 48 conservation partners worldwide.
Named Competitors
CRISPR gene editing — CRISPR-based therapeutics for genetic diseases
Advanced reproductive technology — Genetic engineering and ART for agriculture and therapeutics
Conservation genomics partnerships — Species conservation and habitat restoration initiatives
Recent Developments
(June 2026) Successfully hatched 26 chicks using 3D-printed artificial egg system with silicone-based membrane for avian de-extinction
(April 2025) Announced birth of three dire wolf pups (Romulus, Remus, Khaleesi) created via cloning and gene-editing
(January 2025) Secured $200M Series C funding round led by TWG Global, valuation reached $10.2B, total funding $435M
(October 2024) Established Colossal Foundation as 501(c)(3) nonprofit supporting global conservation initiatives
Open the full interactive Colossal Biosciences report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.